Galmed Pharmaceuticals Ltd (GLMD NASDAQ) stock market data APIs
$1.8149
0.49(27%)
as of July 18, 2025
Try our APIs with
free plan!
Galmed Pharmaceuticals Ltd Financial Data Overview
Price chart is built with
Anychart
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of Aramchol for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule for the treatment of non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study for HIV-associated lipodystrophy and non-alcoholic fatty liver disease. In addition, it develops products for cardiometabolic indications. The company has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with Virginia Commonwealth University to investigate the effect of adding Aramchol to prevent drug resistance to standard-of-care oncology agents in the treatment of hepatoma, cholangiocarcinoma, and colorectal cancer. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Prev. Close
1.8149
Open
2.3027
High
2.3027
Low
1.769
52 wk Range
1.15-15.1
Market Cap
5 261 K
Shares Outstanding
2 258 K
EPS
-0.62
Beta
0.506
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Galmed Pharmaceuticals Ltd data using free add-ons & libraries
Get Galmed Pharmaceuticals Ltd Fundamental Data
Galmed Pharmaceuticals Ltd Fundamental data includes:
- Net Revenue:
- EBITDA: -6 046 250
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-28
- EPS/Forecast: -0.89
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Galmed Pharmaceuticals Ltd News
New
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Protect Your Portfolio Against Market Uncertainty Disco...
10 Oversold Global Stocks To Buy
In this piece, we will take a look at ten oversold global stocks to buy. If you want to skip our analysis of the global economic climate, then take a look at 5 Oversold Global Stocks To Buy. Like Jul...
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada
Endo International plc’s ENDP wholly owned subsidiary, Endo Ventures Limited, has entered into an agreement with Quoin Pharmaceuticals Inc. QNRX for the development, supply, commercialization and di...
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
Aldeyra Therapeutics, Inc. ALDX announced positive data from the vehicle-controlled crossover clinical study which evaluated its investigational product candidate, 0.25% reproxalap ophthalmic solution...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
